FPT Appointed Chief Executive Officer for the French Subsidiary
1.4.2024 10:00:00 EEST | Business Wire | Press release
Global leading IT company FPT recently announced the appointment of Christophe Schwanengel as the Chief Executive Officer of FPT France. The newly appointed CEO is entrusted with the mission of strengthening FPT France’s expansion and diversifying its multi-industry clientele. With further enhanced business growth and reputation in France, as well as other French-speaking countries and territories, the move ultimately aims to realize the company’s ambition to become France's top 50 IT company by 2028.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401898748/en/
(Photo: Business Wire)
According to Dang Tran Phuong, FPT Software’s Senior Executive Vice President for Europe, the Americas, and the Middle East: “We always strive to promote a multicultural work environment. With the appointment of a French industry veteran as CEO, we are optimistic that his deep knowledge of the European IT landscape, together with FPT's existing expertise will deliver high-quality services to our customers, particularly in data services and product engineering”. Phuong emphasized his confidence in FPT France’s breakthroughs in the aviation industry, also driven by the recent acquisition of French IT consulting firm AOSIS to fortify its delivery competencies.
Christophe Schewanegel has over 20 years of experience working in various senior positions. Before joining FPT, he held the position of Vice President of Sales at HCL, where he successfully guided its French division in securing multiple high-profile contracts in the healthcare, aerospace, energy, and manufacturing industries, cumulatively worth over 500 million USD. Prior to that, he was the Business Development Director at CSC, playing a pivotal role in penetrating the European market, facilitating its growth with several million-dollar deals.
Christophe said: “As the new CEO of FPT France, I am committed to building upon FPT Software's established market footprint and reaching new heights in digital transformation for the company and our clients. My primary goal is to drive growth by harnessing our organization's collective strength and global reputation.”
Since entering France in 2008, FPT has affirmed its market position and expertise by partnering with world-leading clients, including Airbus, where the two companies have joined forces in various initiatives to support major aviation players in achieving digital transformation goals since 2017. In 2023, the French subsidiary entered France's top 100 ICT Companies. During the same year, the company also acquired 80% stake in the French IT consulting firm AOSIS, aiming to enhance its capabilities in SAP, Data, Cloud, and smart solutions for aerospace, aviation, and transportation sectors. FPT France plans to expand its presence to other major cities in France with an ambitious goal of covering the entire European region. The company aims to develop a team of over 500 experts, providing timely support for its partners in the country.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology company headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 70,000+ employees. For more information, please visit https://fpt.com.vn/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401898748/en/
Contact information
Media
Mai Duong (Ms.)
FPT Software
PR Manager
MCP.PR@fpt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom